Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Combined hormonal contraception

Essential points for quick revision.

Saved on this device
!
Possible thrombosis or arterial event

New unilateral leg swelling, pleuritic chest pain, breathlessness, haemoptysis, focal neurological deficit, new migraine aura or severe hypertension while using CHC requires urgent assessment.

Action: Stop further CHC pending assessment, use the relevant VTE, stroke or hypertensive-emergency pathway, exclude pregnancy where appropriate, and provide a safe interim contraceptive plan.

Synopsis

Prescribe combined pills, patches and rings safely by applying UKMEC 2025, formulation-specific use and interaction rules while supporting tailored regimens and urgent risk recognition.

  • CHC includes combined oral pills, transdermal patches and vaginal rings; changing route does not avoid oestrogen-related VTE, stroke or migraine-aura restrictions.
  • Current migraine with aura is UKMEC 4; aura at least five years in the past is category 3. Smoking from age 35 is category 3 below 15 cigarettes daily and category 4 at 15 or more.
  • Adequately controlled hypertension or blood pressure 140–159/90–99 mmHg is UKMEC 3 for CHC; blood pressure at least 160 systolic or 100 diastolic, or vascular disease, is category 4.

Key red flags

New migraine aura is current aura and makes every CHC route UKMEC 4 even if previous headaches were labelled migraine without aura.

Chest pain, hypoxia, haemoptysis, unilateral leg swelling or syncope requires urgent VTE assessment rather than an annual pill review.

Focal weakness, speech disturbance, persistent visual deficit or sudden severe headache needs emergency neurological assessment.

Blood pressure at least 160/100 mmHg makes CHC UKMEC 4; repeat accurate measurement must not become a reason to ignore severe symptoms.

Breastfeeding makes CHC UKMEC 4 before six weeks, category 2 from six weeks to under six months, and category 1 from six months on that factor alone; postpartum VTE factors must also be assessed.

A new enzyme inducer can reduce contraceptive efficacy, while oestrogen can lower lamotrigine concentrations and destabilise seizure control.

Venous thrombosis pattern

Unilateral swelling or pain, unexplained breathlessness, pleuritic pain, haemoptysis or collapse suggests DVT or pulmonary embolism.

Arterial event pattern

Focal deficit, speech or visual disturbance, severe sudden headache or cardiac chest pain requires emergency assessment.

Migraine aura

Fully reversible focal visual, sensory or speech symptoms preceding headache differ from nonspecific blur and change CHC eligibility.

Interaction failure risk

Enzyme induction, vomiting, severe diarrhoea or missed use near a hormone-free interval can permit ovulation and trigger emergency-contraception assessment.

Investigation priorities

01
Accurate blood pressureFirst step

Identify category 3 or 4 hypertension before initiation and during continuing use.

Management branches

Initiation pathwayConfirm CHC suitability and chosen regimen

An eligible person requests a combined pill, patch or ring.

  1. Check blood pressure, smoking, migraine aura, BMI, VTE and arterial history, postpartum or breastfeeding status, liver and breast disease and current medicines.
  2. Discuss effectiveness, LARC alternatives, VTE risk, bleeding, hormone-free symptoms and whether standard, shortened, extended or continuous use best fits the selected formulation.

Key medicines

Ethinylestradiol with levonorgestrel combined pillTake one active tablet daily using the licensed schedule or a supported tailored regimen with shortened, less frequent or no hormone-free interval for a monophasic preparation.Confirm the exact strength and product; avoid in UKMEC 4 conditions, review category 3 risks, smoking, blood pressure, migraine aura and interacting medicines.
Combined transdermal patch or vaginal ringApply or insert on the product-specific weekly or three-week schedule, replacing a detached patch or delayed ring according to its missed-use instructions.Non-oral use does not remove vascular contraindications or enzyme-inducer interactions; confirm adhesion, expulsion, storage and backup rules.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom